FDC Int recalls a batch of sodium cromoglicate eye drops and of Murine Hayfever Relief

FDC Int recalls a batch of sodium cromoglicate eye drops and of Murine Hayfever Relief

July 31 2018 A class 3 recall for sodium cromoglicate 2% w/v eye drops and Murine Hayfever Relief...

Effect of omega-3 on heart disease is negligible, finds Cochrane review

Effect of omega-3 on heart disease is negligible, finds Cochrane review

July 19 2018 Cochrane researchers have published research indicating that omega 3 supplements...

BLF highlights decline in stop smoking prescriptions

BLF highlights decline in stop smoking prescriptions

July 18 2018 There has been a 75% decline in stop smoking treatments being prescribed by GPs and...

Welsh National Survey includes OTC medicine purchases for first time

Welsh National Survey includes OTC medicine purchases for first time

June 28 2018 Over half the population in Wales has reported having bought an over the counter...

Recall issued for several own label glycerine and blackcurrant cough syrups

Recall issued for several own label glycerine and blackcurrant cough syrups

June 20 2018 A Class 2 Drug Recall has been issued for 15 batches of own-brand children’s...

  • FDC Int recalls a batch of sodium cromoglicate eye drops and of Murine Hayfever Relief

    FDC Int recalls a batch of sodium cromoglicate eye drops and of Murine Hayfever Relief

    Tuesday, 31 July 2018 15:24
  • Effect of omega-3 on heart disease is negligible, finds Cochrane review

    Effect of omega-3 on heart disease is negligible, finds Cochrane review

    Thursday, 19 July 2018 10:21
  • BLF highlights decline in stop smoking prescriptions

    BLF highlights decline in stop smoking prescriptions

    Wednesday, 18 July 2018 17:32
  • Welsh National Survey includes OTC medicine purchases for first time

    Welsh National Survey includes OTC medicine purchases for first time

    Thursday, 28 June 2018 16:55
  • Recall issued for several own label glycerine and blackcurrant cough syrups

    Recall issued for several own label glycerine and blackcurrant cough syrups

    Wednesday, 20 June 2018 18:29

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a psoriasis hand imageSeptember 20 2017

Leo Pharma has announced it will not now launch an over-the-counter version of Dovonex Psoriasis Ointment, despite recently receiving authorisation to do so.

 Last month, the medicines regulator, the MHRA, announced that it had approved the application for a Pharmacy only product. Dovonex Psoriasis Ointment containing calcipotriol 50microgrammes/g was to be available in a 60g tube for adults “with mild to moderate plaque psoriasis which has been previously diagnosed by a doctor.”

However, Leo Pharma UK and Ireland has now announced that it will not launch the OTC product in the UK. The original Prescription Only Medicine version will remain available for the topical treatment of plaque psoriasis (psoriasis vulgaris) amenable to topical therapy.

Explaining its decision, the company said: “The reason for this new approach is that our commercial and strategic priorities have evolved with the introduction of our new strategy towards 2025.

“Whilst our legacy is firmly grounded in topical treatments, and we continue to invest in our successful topical therapy portfolio, our focus is moving towards strengthening our capabilities and priorities around our new emerging dermatology systemic portfolio. This will help us with our ultimate mission to help people achieve healthy skin by expanding our treatment offering to further meet the needs of people with skin diseases.”

Link:
Leo Pharma UK  
Today’s Pharmacist coverage of MHRA announcement (August 22 2017)

OTC News

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...